A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
Stopped Because of many competing trials using the same mechanism of action, but being further advanced in development
Conditions
- Chronic Hepatitis C Infection
Interventions
- DRUG: JNJ-47910382 30 mg
- DRUG: JNJ-47910382 90 mg
- DRUG: JNJ-47910382 200 mg
- DRUG: Placebo
Sponsor
Janssen R&D Ireland